申请人:Schering Aktiengesellschaft
公开号:US04894377A1
公开(公告)日:1990-01-16
.beta.-Carbolines of general Formula I ##STR1## wherein R.sup.3 is ##STR2## or --COOR", wherein R' is C.sub.1-3 alkyl or C.sub.3-6 cycloalkyl and R" is C.sub.1-4 alkyl; R.sup.4 is hydrogen, methyl, ethyl or methoxymethyl; and R.sup.A is ##STR3## wherein X is C.sub.1-12 straight-chain, branched-chain, saturated or unsaturated alkyl or a corresponding alkyl group with a CH.sub.2 -group substituted by a carbonyl group and R"" is one or more of fluorine, chlorine, bromine, or iodine, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, C.sub.1-5 acyloxy, phenyl, C.sub.2-5 alkylenedioxy, trifluoromethyl, nitrilo, nitro or --NR.sup.IV R.sup.V wherein R.sup.IV and R.sup.V, which can be the same or different are hydrogen, C.sub.1-3 alkyl, C.sub.1-5 acyl or phenyl, or collectively with the amido nitrogen atom form a 3- to 6-membered hetero ring, which are prepared conventionally by esterifying a corresponding compound wherein R.sup.A is H or R.sup.3 is --COOH, exhibit effects on the central nervous system and can be used as psychorharmaceuticals.
一般式为I的.beta.-Carbolines
##STR1##
其中R.sup.3是##STR2##或--COOR",其中R'是C.sub.1-3烷基或C.sub.3-6环烷基,R"是C.sub.1-4烷基;R.sup.4是氢,甲基,乙基或甲氧基甲基;R.sup.A是##STR3##
其中X是C.sub.1-12直链、支链、饱和或不饱和烷基或相应的烷基,其CH.sub.2基被羰基基团取代,R""是氟、氯、溴或碘、C.sub.1-3烷基、C.sub.1-3烷氧基、C.sub.1-5酰氧基、苯基、C.sub.2-5烷基二氧基、三氟甲基、硝基、或--NR.sup.IV R.sup.V,其中R.sup.IV和R.sup.V,可以相同或不同,是氢、C.sub.1-3烷基、C.sub.1-5酰基或苯基,或与酰胺氮原子共同形成3-6成员杂环的制备方法通常通过酯化R.sup.A是H或R.sup.3是--COOH的相应化合物而制备,对中枢神经系统产生作用,并可用作精神药物。